About 20% of patients suffering from breast cancer , do not finish the hormone therapy, researchers reported at the congress in Singapore.
Adjuvant endocrine therapy to prevent recurrence and improves survival rates by 5-10% in patients with estrogen receptor in breast cancer, particularly when administered within 5-10 years, says Wahoo Vulaninsih, a researcher at University College London.
The study involved 5544 women with cancer of the breast, which prescribed tamoxifen or an aromatase inhibitor. Recipe information obtained from the regional registries of Uppsala-Örebro, Stockholm-Gotland and northern Sweden, which cover 60% of the population. Compliance with the treatment was calculated from prescription drugs, patients were classified as non-compliance treatment if they received at least 80% of drugs that are needed within five years.
In the analysis of the factors influencing non-compliance with treatment: early age, previous use of hormone therapy, marital status, and socioeconomic status (as measured by employment type).
Women younger than 50 years on 50% more likely to not adhere to treatment, compared with 50-65-year-olds. The same applies to unmarried and unemployed women, who do not fully passed the course of therapy.
According Vulaninsih, breast cancer patients of childbearing age are concerned about the potential impact of endocrine therapy on fertility, which explains why they are more likely to stop taking the medication. Women who want to have children after a diagnosis of breast -rak, need more information about treatment options.
Vulaninsih suggested that unmarried patients have less social and emotional support to continue hormone therapy.
According to the expert, the study found a subgroup of patients who need information about the benefits and consequences of endocrine treatment. It is necessary to develop support groups to help patients overcome barriers to continuing treatment.
Commenting on the findings, Dr Lim Si Ng, senior consultant of the Department of Hematology and Oncology, Cancer Institute in Singapore, says: Failure of hormone therapy is associated with a high recurrence rate and is an important risk factor that can influence the effects of breast cancer. This study identified the social and economic factors, not a disease or medical factors as the treatment of non-compliance risks. They identify a group of patients for which strict control and management of side effects is needed for the full course of therapy.